×

PRA Named Clinical Company of the Year

RALEIGH, N.C., June 8, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to announce that it was once again recognized as the Best Clinical Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Cary, North Carolina. This award follows PRA's recognition as the Best International Clinical Company of the Year which was announced earlier this year in London.

In addition to the recognition received by the company, several PRA employees received individual gold awards:

  • New CRA: Jo-Zahn Baxter
  • Experienced CRA: Velma Reed
  • Clinical Team: Ben Bolton, Kim Mohres, Sherry Palmateer, Deb Rork, Theresa Sampson

"PRA is honored to be named Clinical Company of the Year," said Michael Brooks, PRA senior vice president product registration, Americas. "We are immensely proud of all the many talented and dedicated employees who made this prestigious recognition possible."

Organized by PharmaTimes, the Clinical Researcher of the Year competition is considered a key barometer of quality standards in the Clinical Research Organization (CRO) industry. The multi-stage competition is organized by an independent executive steering committee drawn from senior industry leaders from big and small pharma, leading CROs and professional membership associations.

ABOUT PRA HEALTH SCIENCES

PRA Health Sciences is one of the world's leading global contract research organizations, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. At PRA, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.

CONTACT: MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: rogerschristine@prahs.com PHONE: +1 919.786.8463 INVESTOR INQUIRIES: InvestorRelations@prahs.com Global Headquarters 4130 ParkLake Avenue, Suite 400 Raleigh, North Carolina USA PHONE: +1 919.786.8200 www.prahs.com

Source:PRA Health Sciences